Hepatocellular carcinoma (HCC) is the third most common cause of cancer‐related death
and occurs mainly in the context of chronic liver disease at cirrhosis stage. The Barcelona …

Simple Summary Hepatocellular carcinoma is the most common liver cancer, leading to
approximately 700,000 deaths worldwide and 30,000 deaths in the United States every …

Objectives This study aimed to investigate the efficacy and safety of transarterial
chemoembolization (TACE) plus camrelizumab, a monoclonal antibody targeting …

Background CT-guided high-dose-rate (HDR) brachytherapy (hereafter, HDR
brachytherapy) has been shown to be safe and effective for patients with unresectable …

The Barcelona Clinic Liver Cancer (BCLC) system, initially proposed in 1999, is certainly the
most commonly used staging system for HCC in Western countries. Just a few days ago, the …

Objectives To compare the efficacy, overall survival (OS) and safety of drug-eluting beads-
TACE (DEB-TACE) and C-TACE as initial treatment in advanced hepatocellular carcinoma …

Cone-beam computed tomography (CBCT) has emerged as a prominent imaging modality
in interventional radiology that offers real-time visualization and precise guidance in various …

Hepatocellular carcinoma (HCC) is the most common primary liver cancer and the 3 rd
leading cause of cancer death worldwide. Treatment options include surgical resection, liver …

CIREL, a prospective, Europe-wide, observational study aimed to assess the real-world
feasibility and tolerability of irinotecan-based transarterial chemoembolization (LP-irinotecan …

Hepatocellular carcinoma (HCC) is one of the major malignant diseases worldwide,
characterized by growing incidence and high mortality rates despite apparent improvements …